CN113543771A - 用于错误折叠蛋白质成像的功能化脂质体 - Google Patents

用于错误折叠蛋白质成像的功能化脂质体 Download PDF

Info

Publication number
CN113543771A
CN113543771A CN202080018762.8A CN202080018762A CN113543771A CN 113543771 A CN113543771 A CN 113543771A CN 202080018762 A CN202080018762 A CN 202080018762A CN 113543771 A CN113543771 A CN 113543771A
Authority
CN
China
Prior art keywords
alkyl
carboxy
amino
independently
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080018762.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·V·安娜普拉戈达
P·尼尔森
C·美第奇
E·A·塔尼夫姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alzeca Biosciences LLC
Original Assignee
Alzeca Biosciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzeca Biosciences LLC filed Critical Alzeca Biosciences LLC
Publication of CN113543771A publication Critical patent/CN113543771A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN202080018762.8A 2019-01-24 2020-01-24 用于错误折叠蛋白质成像的功能化脂质体 Pending CN113543771A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962796198P 2019-01-24 2019-01-24
US201962796196P 2019-01-24 2019-01-24
US201962796186P 2019-01-24 2019-01-24
US201962796201P 2019-01-24 2019-01-24
US201962796189P 2019-01-24 2019-01-24
US201962796193P 2019-01-24 2019-01-24
US62/796,189 2019-01-24
US62/796,201 2019-01-24
US62/796,198 2019-01-24
US62/796,186 2019-01-24
US62/796,193 2019-01-24
US62/796,196 2019-01-24
US201962828669P 2019-04-03 2019-04-03
US62/828,669 2019-04-03
PCT/US2020/014995 WO2020154623A1 (en) 2019-01-24 2020-01-24 Functionalized liposomes for imaging misfolded proteins

Publications (1)

Publication Number Publication Date
CN113543771A true CN113543771A (zh) 2021-10-22

Family

ID=71737450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080018762.8A Pending CN113543771A (zh) 2019-01-24 2020-01-24 用于错误折叠蛋白质成像的功能化脂质体

Country Status (5)

Country Link
US (1) US20200261605A1 (https=)
EP (1) EP3914230A4 (https=)
JP (1) JP7545393B2 (https=)
CN (1) CN113543771A (https=)
WO (1) WO2020154623A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
JP2025515115A (ja) * 2022-05-06 2025-05-13 テキサス チルドレンズ ホスピタル タウ病態のための標的化リガンド

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256959A (zh) * 2008-10-17 2011-11-23 比奥克罗密克斯药业有限公司 用于治疗的新型噻吩化合物
CN104144708A (zh) * 2011-04-06 2014-11-12 德克萨斯大学系统董事会 基于脂质的纳米粒子
CN106362171A (zh) * 2009-02-13 2017-02-01 华盛顿大学 用于磁共振成像的钆表现脂质纳米颗粒
CN107106708A (zh) * 2014-10-08 2017-08-29 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256959A (zh) * 2008-10-17 2011-11-23 比奥克罗密克斯药业有限公司 用于治疗的新型噻吩化合物
CN106362171A (zh) * 2009-02-13 2017-02-01 华盛顿大学 用于磁共振成像的钆表现脂质纳米颗粒
CN104144708A (zh) * 2011-04-06 2014-11-12 德克萨斯大学系统董事会 基于脂质的纳米粒子
CN107106708A (zh) * 2014-10-08 2017-08-29 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ERIC A. TANIFUMA: "A Novel Liposomal Nanoparticle for the Imaging of Amyloid Plaque by Magnetic Resonance Imaging", JOURNAL OF ALZHEIMER’S DISEASE, vol. 52, no. 2, 10 May 2016 (2016-05-10), pages 731 - 745, XP055477335, DOI: 10.3233/JAD-151124 *

Also Published As

Publication number Publication date
US20200261605A1 (en) 2020-08-20
EP3914230A1 (en) 2021-12-01
WO2020154623A1 (en) 2020-07-30
JP2022523056A (ja) 2022-04-21
EP3914230A4 (en) 2023-06-07
JP7545393B2 (ja) 2024-09-04

Similar Documents

Publication Publication Date Title
AU2021203388B2 (en) MRI Imaging Of Amyloid Plaque Using Liposomes
TWI699358B (zh) 用於磁共振照影之新穎釓螯合化合物
Anbu et al. A Single‐Pot Template Reaction Towards a Manganese‐Based T1 Contrast Agent
CN113543771A (zh) 用于错误折叠蛋白质成像的功能化脂质体
JP7034160B2 (ja) 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
Licciardi et al. Large protein assemblies for high-relaxivity contrast agents: the case of gadolinium-labeled asparaginase
CN107949383A (zh) 用于成像的含氮氧化合物的淀粉样蛋白结合剂和治疗用途
US20210252170A1 (en) Targeted contrast agents for mri of alpha-synuclein deposition
US20230136718A1 (en) Functionalized liposomes for imaging misfolded proteins
US11779664B2 (en) Targeted contrast agents for MRI of alpha-synuclein deposition
CN118791488B (zh) 化合物、螯合物及其在磁共振成像中的应用
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
US20240226342A1 (en) Reactive oxygen species imaging agents
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
HK1243335B (zh) 使用脂质体进行的淀粉样蛋白斑mri成像

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211022

WD01 Invention patent application deemed withdrawn after publication